Concepedia

O. Davies

OD

24

Publications

2.7K

Citations

19

H-Index

2008

Active since

Affiliations

UCB Pharma (United Kingdom)(Current)

UCB Pharma (Germany)

Leiden University Medical Center

Charité - Universitätsmedizin Berlin

UCB Pharma (Belgium)

O. Davies is an author at UCB Pharma (United Kingdom) specializing in covid-19, medicine, and epidemiology.

Top concepts

Publications per year

2008–2024

24

Publications

24

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Eugenia Abaleke, Mustafa Abbas, Sadia Abbasi et al. · The Lancet · 2021 · 555 citations · Full text

, , +7

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Obbina Abani, Ali Abbas, Fatima Abbas et al. · The Lancet · 2021 · 516 citations · Full text

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani, Ali Abbas, Fatima Abbas et al. · The Lancet · 2022 · 382 citations · Full text

, , +3

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Obbina Abani, Ali Abbas, Fatima Abbas et al. · The Lancet · 2021 · 289 citations · Full text

Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial

Désirée van der Heijde, Xenofon Baraliakos, Kay‐Geert Hermann et al. · Annals of the Rheumatic Diseases · 2018 · 128 citations · Full text

Rows per page

1–5 of 24